RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On June 6, 2017, RespireRx Pharmaceuticals Inc. (the Company)
announced that the Companys Senior Vice President of Research and
Development, Richard Purcell, will be presenting a poster session
entitled OPIOIDS AND SLEEP APNEA: ANTAGONISM OF REMIFENTANIL
INDUCED RESPIRATORY DEPRESSION BY CX1739 IN TWO CLINICAL MODELS
OF OPIOID INDUCED RESPIRATORY DEPRESSION at the Sleep 2017
conference in Boston, MA on June 6, 2017 from 5:00 to 7:00 p.m.
Eastern Time. SLEEP 2017 is the 31st Annual Meeting of the
Associated Professional Sleep Societies LLC, a joint venture of
theAmerican Academy of Sleep Medicineand theSleep Research
Society.
The content of the poster that Mr. Purcell will be using at the
conference is attached as Exhibit 99.1 and is being furnished and
not filed to Item 7.01 of Form 8-K. The press release announcing
the Companys participation in the conference is attached as
Exhibit 99.2 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
A list of exhibits that are furnished and filed as part of this
report is set forth in the Exhibit Index, which is presented
elsewhere in this document, and is incorporated herein by
reference.
About RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI)
RespireRx Pharmaceuticals Inc., formerly Cortex Pharmaceuticals, Inc., is engaged in the discovery, development and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The Company is focused on the clinical development in the areas of respiratory disorders, including respiratory depression and sleep apnea. It is engaged in research and clinical development of a class of compounds referred to as ampakines, which act to enhance the actions of the excitatory neurotransmitter glutamate at a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors. Its ampakines, including CX717, CX1739 and CX1942, were efficacious in treating drug induced respiratory depression caused by opioids or certain anesthetics without offsetting the analgesic effects of the opioids or the anesthetic effects of the anesthetics. Its dronabinol is indicated for the treatment of sleep-related breathing disorders, including sleep apnea.